Global Self-Injections Market Outlook (2018-2024) by Top Industry Vendors Like Antares Pharma, 3M, Becton Dickinson & Company, Baxter International Inc. and More

Global Self-Injections Market, By Type (Devices (Needle-Free, Auto, Pen, Wearable Injectors), Formulations), Dosage Form, Therapeutic Application, Route of Administration, End-User, Distribution Channel,Geography(North America, Europe, APAC, MEA, South America) and Forecast to 2024.

Get Free Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-self-injections-market

Global Self-Injections Market is expected to reach USD 119.5 billion by 2024, from USD 23.4 billion in 2016 growing at a CAGR of 22.6% in the forecast period 2017 to 2024.

Top Companies Mentioned:

• Abbvie, Inc.
• Antares Pharma
• 3M
• Becton Dickinson & Company
• Baxter International Inc.
• Penjet Corporation
• PharmaJet
• GerresheimerAG
• Pfizer Inc.
• Terumo Corporation
• Mylan N.V.
• SHL Group
• Bespak
• Janssen Biotech Inc.
• Insulet Corporation
• Unilife Corporation
• West Pharmaceutical Services, Inc.
• Ypsomed
• Eli lilly and Company
• Haselmeier AG
• Alkermes
• AptarPharma
• Credence MedSystems, Inc.
• SchottAG
• Owen Mumford Ltd.
• Glide Technologies

Competitive Landscape:

The global self-injections market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their positions in the market.

For More Details In-Depth Inquiry @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-self-injections-market

Scope of the Report:

The self-injections market is segmented based on type, dosage form, and therapeutic application, route of administration, end-user, distribution channel, and geography.

On the basis of type, the global self-injections market is segmented into devices and formulations. The devices market is segmented into needle-free injectors, auto injectors, pen injectors, wearable injectors, and other devices.

The formulations market is segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting formulations.
The needle-free injectors market is further segmented on the basis of product, technology, and usability. The product segment is categorized into fillable and prefilled. The technology segment is further categorized into jet-based, spring-based, laser-powered, and vibration-based. The usability segment is further categorized into reusable and disposable.

Based on therapeutic application, the global self-injections market is segmented intoautoimmunediseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others. The market is also segmented based on dosage formintosingle dose and multi-dose.

On the basis of route of administration, the global self-injections market is segmented into skin, circulatory /musculoskeletal, organs, and central nervous system.

On the basis of end-user, the global self-injections market is segmented into patient, physicians, home care settings and, others. The market is also segmented on the basis of distribution channel into hospital pharmacies, private clinics, chemist, and online pharmacies.

Based on geography the global self-injections market is segmented into:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
• Rest of the World

View Full Report @ http://databridgemarketresearch.com/reports/global-self-injections-market-/

Key Topics Covered:

1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL SELF-INJECTION MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. HIGH COST OF DEVELOPMENT
3.2.2. STRICT REGULATORY FRAMEWORK

3.3. OPPORTUNITY

3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS

3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS

3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL SELF-INJECTION MARKET, REGULATORY

6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)

7. GLOBAL SELF-INJECTION MARKET, REIMBUSEMENT

7.1. OVERVIEW
7.2. REIMBURSEMENT SCENARIO

8. GLOBAL SELF-INJECTION MARKET, BY TYPE

8.1. OVERVIEW

8.2. GLOBAL SELF-INJECTION MARKET, BY PRODUCT TYPE

8.2.1. NEEDLE FREE INJECTORS (NFI)

8.2.1.1. NEEDLE FREE INJECTORS, BY PRODUCT
8.2.1.2. NEEDLE FREE INJECTORS, BY TECHNOLOGY LASER BASED NEEDLE FREE INJECTORS:VIBRATION BASED NEEDLE FREE INJECTORS:
8.2.1.3. NEEDLE FREE INJECTORS, BY USABILITY REUSABLE NEEDLE-FREE INJECTORS DISPOSABLE NEEDLE-FREE INJECTORS

8.2.2. AUTO INJECTORS

8.2.2.1. AUTO INJECTORS, BY PRODUCT FILLABLE AUTO INJECTORS PRE-FILLED AUTO INJECTORS
8.2.2.2. AUTO INJECTORS, BY TECHNOLOGY AUTOMATED AUTO INJECTORS MANUAL AUTO INJECTORS
8.2.2.3. AUTO INJECTORS, BY DESIGN STANDARDIZED AUTO INJECTORS CUSTOMIZEDAUTO INJECTORS
8.2.2.4. AUTO INJECTORS, BY USABILITY REUSABLE AUTO INJECTORS DISPOSABLE AUTO INJECTORS

8.2.3. PEN INJECTORS

8.2.3.1. PEN INJECTORS, BY PRODUCT SINGLE CHAMBERED PEN INJECTORS DUAL CHAMBERED PEN INJECTORS
8.2.3.2. PEN INJECTORS, BY DESIGN STANDARD PEN INJECTORS CUSTOMIZED PEN INJECTORS
8.2.3.3. PEN INJECTORS, BY USABILITY REUSABLE PEN INJECTORS DISPOSABLE PEN INJECTORS

8.2.4. WEARABLE INJECTORS

9. GLOBAL SELF-INJECTION MARKET, BY APPLICATION

9.1. OVERVIEW

9.2. GLOBAL SELF-INJECTION MARKET, BY APPLICATION

9.3. HORMONAL DISORDERS

9.3.1. SELF-INJECTIONS FOR DIABETES
9.3.2. SELF-INJECTIONSFOR ANEMIA
9.3.3. REPRODUCTIVE HEALTH DISEASE
9.3.4. OSTEOPOROSIS
9.3.5. GROWTH HORMONE DISORDERS (GHD)

9.4. ONCOLOGY

9.5. AUTOIMMUNE DISEASES

9.5.1. RHEUMATOID ARTHRITIS
9.5.2. MULTIPLE SCLEROSIS
9.5.3. CROHN’S DISEASES
9.5.4. PSORIASIS
9.5.5. OTHER AUTOIMMUNE DISEASES

9.6. ORPHAN DISEASE

9.7. OTHER APPLICATIONS

9.7.1. PAIN MANAGEMENT
9.7.2. ALLERGY TREATMENT
9.7.3. AESTHETIC TREATMENTS
9.7.4. HEPATITIS C
9.7.5. HEMOPHILIA

10. GLOBAL SELF-INJECTION MARKET, BY USAGE PATTERN

10.1. OVERVIEW
10.2. CURATIVE CARE
10.3. IMMUNIZATIONS
10.4. OTHER USAGE PATTERN

11. GLOBAL SELF-INJECTION MARKET, BY MODE OF ADMINISTRATION

11.1. OVERVIEW
11.2. SKIN
11.3. CIRCULATORY/ MUSKOSKELETAL
11.4. ORGANS
11.5. CENTRAL NERVOUS SYSTEM

12. GLOBAL SELF-INJECTION MARKET, BY END USER

12.1. OVERVIEW
12.2. HOSPITALS AND CLINICS
12.3. HOME HEALTHCARE SETTINGS
12.4. RESEARCH LABORATORIES
12.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
12.6. OTHER END USER

13. GLOBAL SELF-INJECTION MARKET, BY DISTRIBUTION CHANNEL

13.1. OVERVIEW
13.1.1. HOSPITAL PHARMACY
13.1.2. PHARMACY STORES
13.1.3. DIRECT TENDER
13.1.4. ONLINE PHARMACY

14. GLOBAL SELF-INJECTION MARKET, BY GEOGRAPHY

14.1. OVERVIEW

14.2. NORTH AMERICA

14.2.1. U.S.
14.2.2. CANADA
14.2.3. MEXICO

14.3. EUROPE

14.3.1. GERMANY
14.3.2. FRANCE
14.3.3. UK
14.3.4. SWITZERLAND
14.3.5. SPAIN
14.3.6. ITALY
14.3.7. NETHERLANDS
14.3.8. RUSSIA
14.3.9. TURKEY
14.3.10. BELGIUM
14.3.11. REST OF EUROPE

14.4. APAC

14.4.1. JAPAN
14.4.2. CHINA
14.4.3. SOUTH KOREA
14.4.4. INDIA
14.4.5. AUSTRALIA
14.4.6. SINGAPORE
14.4.7. THAILAND
14.4.8. MALAYSIA
14.4.9. INDONESIA
14.4.10. PHILIPPINES
14.4.11. REST OF APAC

14.5. SOUTH AMERICA

14.5.1. BRAZIL
14.5.2. REST OF SOUTH AMERICA

14.6. MEA

14.6.1. SOUTH AFRICA
14.6.2. REST OF MEA

15. GLOBAL SELF INJECTION MARKET, COMPANY LANDSCAPE

15.1. COMPANY SHARE ANALYSIS: GLOBAL
15.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3. COMPANY SHARE ANALYSIS: EUROPE
15.4. COMPANY SHARE ANALYSIS: APAC

16. COMPANY PROFILES

16.1. ELCAM MEDICALCOMPANY OVERVIEW

16.1.1. ELCAM MEDICAL: COMPANY SNAPSHOT
16.1.2. PRODUCT PORTFOLIO
16.1.3. RECENT DEVELOPMENTS

16.2. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)

16.2.1. COMPANY OVERVIEW
16.2.2. BESPAK: REVENUE ANALYSIS
16.2.3. PRODUCT PORTFOLIO
16.2.4. RECENT DEVELOPMENTS

16.3. SANOFI

16.3.1. COMPANY OVERVIEW
16.3.2. SANOFI : REVENUE ANALYSI
16.3.3. PRODUCT PORTFOLIO
16.3.4. RECENT DEVELOPMENTS

16.4. SANDOZ INTERNATIONAL GMBH

16.4.1. COMPANY OVERVIEW

16.5. SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS

16.5.1. PRODUCT PORTFOLIO
16.5.2. RECENT DEVELOPMENTS

16.6. UNILIFE CORPORATION

16.6.1. COMPANY OVERVIEW
16.6.2. UNILIFE CORPORATION: REVENUEANALYSIS
16.6.3. PRODUCT PORTFOLIO
16.6.4. RECENT DEVELOPMENTS

16.7. WEST PHARMACEUTICAL SERVICES, INC

16.7.1. COMPANY OVERVIEW
16.7.2. WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS
16.7.3. PRODUCT PORTFOLIO
16.7.4. RECENT DEVELOPMENTS

16.8. PFIZER INC.

16.8.1. COMPANY OVERVIEW
16.8.2. PFIZER INC: REVENUE ANALYSIS
16.8.3. PRODUCT PORTFOLIO
16.8.4. RECENT DEVELOPMENTS

16.9. IMPAX LABORATORIES, INC.

16.9.1. COMPANY OVERVIEW
16.9.2. IMPAX LABORATORIES, INC: REVENUE ANALYSIS
16.9.3. PRODUCT PORTFOLIO
16.9.4. RECENT DEVELOPMENTS

16.10. PENJET CORPORATION

16.10.1. COMPANY OVERVIEW
16.10.2. PENJET CORPORATION: COMPANY SNAPSHOT
16.10.3. PRODUCT PORTFOLIO
16.10.4. RECENT DEVELOPMENTS

16.11. CROSSJECT NEEDLE-FREE INJECTION SYSTEMS

16.11.1. COMPANY OVERVIEW
16.11.2. CROSSJECT NEEDLE-FREE INJECTION SYSTEMS: COMPANY SNAPSHOT
16.11.3. PRODUCT PORTFOLIO
16.11.4. RECENT DEVELOPMENTS

16.12. WILHELM HASELMEIER GMBH & CO. KG

16.12.1. COMPANY OVERVIEW
16.12.2. HASELMEIER: COMPANY SNAPSHOT
16.12.3. PRODUCT PORTFOLIO
16.12.4. RECENT DEVELOPMENTS

16.13. ANTARES PHARMA

16.13.1. COMPANY OVERVIEW
16.13.2. ANTARES PHARMA: REVENUE ANALYSIS
16.13.3. PRODUCT PORTFOLIO
16.13.4. RECENT DEVELOPMENTS

16.14. BECTON, DICKINSON AND COMPANY

16.14.1. COMPANY OVERVIEW
16.14.2. BECTON, DICKINSON AND COMPANY: REVENUE ANALYSIS
16.14.3. PRODUCT PORTFOLIO
16.14.4. RECENT DEVELOPMENTS

16.15. GERRESHEIMER AG

16.15.1. COMPANY OVERVIEW
16.15.2. GERRESHEIMER AG: REVENUE ANALYSIS
16.15.3. PRODUCT PORTFOLIO
16.15.4. RECENT DEVELOPMENTS

16.16. MYLAN N.V

16.16.1. COMPANY OVERVIEW
16.16.2. MYLAN N.V.: REVENUE ANALYSIS
16.16.3. PRODUCT PORTFOLIO
16.16.4. RECENT DEVELOPMENTS

16.17. NOVO NORDISK

16.17.1. COMPANY OVERVIEW
16.17.2. NOVO NORDISK: REVENUE ANALYSIS
16.17.3. PRODUCT PORTFOLIO
16.17.4. RECENT DEVELOPMENTS

16.18. OWEN MUMFORD LTD

16.18.1. COMPANY OVERVIEW
16.18.2. OWEN MUMFORD LTD: COMPANY SNAPSHOT
16.18.3. PRODUCT PORTFOLIO
16.18.4. RECENT DEVELOPMENTS

16.19. PHARMAJET

16.19.1. COMPANY OVERVIEW
16.19.2. PHARMAJET: COMPANY SNAPSHOT
16.19.3. PRODUCT PORTFOLIO
16.19.4. RECENT DEVELOPMENTS

16.20. SHL GROUP

16.20.1. COMPANY OVERVIEW
16.20.2. SHL GROUP: COMPANY SNAPSHOT
16.20.3. PRODUCT PORTFOLIO
16.20.4. RECENT DEVELOPMENTS

16.21. YPSOMED

16.21.1. COMPANY OVERVIEW
16.21.2. YPSOMED: REVENUE ANALYSIS
16.21.3. PRODUCT PORTFOLIO
16.21.4. RECENT DEVELOPMENTS

Related Report

Global Human Insulin Drugs and Delivery Devices Market – Industry Trends and Forecast to 2024

Global Human Insulin Drugs and Delivery Devices Market, By Product Type, By End-User, By Distribution Channel, By Geography (North America, South America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA)) – Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-human-insulin-drugs-and-delivery-devices-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.